Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, China; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
Chin Clin Oncol. 2022 Aug;11(4):29. doi: 10.21037/cco-22-18.
Glioma is the most common intracranial primary malignant tumor, and half of it is glioblastoma. Despite receiving the standard treatment, the prognosis of glioblastoma is still poor and its 5-year survival rate in China is only 9%. In addition, new targeted and immunotherapy therapy and tumor treating fields also have certain curative effects on glioblastoma. To help clinicians and patients make appropriate treatment based on current evidences, we summarize the Chinese guidelines on the management of glioma and review the recent management of glioblastoma.
We systematically searched PubMed, China National Knowledge Infrastructure (CNKI) and Wanfang databases to retrieve guidelines on glioma in China published from the establishment of the database to 24 January 2022. We performed a narrative review of current clinical study related to the management of glioblastoma, especially in the surgical, targeted and immunotherapy therapy and tumor treating fields.
In this review, 19 guidelines were included, including 8 subclassified as the guideline, 8 subclassified as the consensus and 3 subclassified as the standard. Two guidelines reported the contents of the system search, 4 guidelines are updated, and 9 guidelines reported the source of funding. At present, most clinical trials on the immune and targeted therapy of glioblastoma are ongoing in China.
China's guidelines still need to be improved in terms of preciseness, applicability and editorial independence. In addition, the cooperation in clinical research of glioblastoma in multiple centers needs to be strengthened in China.
脑胶质瘤是最常见的颅内原发性恶性肿瘤，其中半数为胶质母细胞瘤。尽管接受了标准治疗，胶质母细胞瘤的预后仍然较差，其在中国的 5 年生存率仅为 9%。此外，新的靶向和免疫治疗以及肿瘤电场治疗对胶质母细胞瘤也有一定疗效。为帮助临床医生和患者根据现有证据做出适当的治疗决策，我们总结了中国脑胶质瘤诊疗指南，并对胶质母细胞瘤的最新治疗进展进行了综述。
我们系统地检索了 PubMed、中国知网（CNKI）和万方数据库，以检索从数据库建立到 2022 年 1 月 24 日发布的中国脑胶质瘤相关指南。我们对目前与胶质母细胞瘤治疗相关的临床研究进行了叙述性综述，特别是在手术、靶向和免疫治疗以及肿瘤电场治疗方面。
本综述共纳入 19 项指南，其中 8 项被归类为指南，8 项被归类为共识，3 项被归类为标准。有 2 项指南报告了系统检索的内容，4 项指南进行了更新，9 项指南报告了资金来源。目前，中国正在进行多项胶质母细胞瘤免疫和靶向治疗的临床试验。
中国的指南在准确性、适用性和编辑独立性方面仍有待提高。此外，中国还需要加强多中心胶质母细胞瘤临床研究的合作。
